Neuromuscular HOMEepAGE
neuromuscular.wustl.edu
/
A–Z

III. Testing Laboratory Standards for anti-MAG Antibodies.

Immune/Antibody
W
View full entry on WUSTL Neuromuscular
antibody/mag.html#III. Testing Laboratory Standards for anti-MAG Antibodies.

Overview

From WUSTL Neuromuscular

Optimal testing utilizes: Highest sensitivity ELISA screening methods with highly purified MAG1 Highest specificity Western blot confirmation of positive results > 85% correlation with ELISA Sub-optimal procedures: Low sensitivity: Initial screening vs glycolipids using thin-layer chromatography. ELISA assays with Short antibody binding periods less than 5 hours, or procedures conducted at room temperature (optimal at 4 °C). Low specificity: Testing only by ELISA without Western blot confirmation. ELISA assays utilizing semi-pure MAG containing lipid impurities. The sensitivity of anti-MAG ant

Related Conditions

Shared genes
Antibodies vs Glycolipids & Glycoproteins
GM1MAGGQ1B
Axonal Sensory Neuropathies with Serum IgM binding to Trisulfated Heparin Disaccharide (TS-HDS)
HDSDISACCHARIDEMAG
I. Clinical Indications for Measurement of anti-MAG antibodies
MAG
II. Results with Specificity and Sensitivity for Sensory-Motor Neuropathies
MAG
IV. Interpretations of Confirmed Positive anti-MAG Results
MAG
IV. Positive Result: Clinical Utility and Interpretations
MAG
Monoclonal Gammopathies of Unknown Significance (& Other)
MAGGD1AHDS
Myelin Glycoproteins
MAG

External Resources

WUSTL Neuromuscular
Washington University Disease Center
PubMed
Biomedical Literature
GeneReviews
NCBI Expert-Authored Reviews
Orphanet
Portal for Rare Diseases
NORD
National Organization for Rare Disorders

Data sourced from the Washington University Neuromuscular Disease Center. For clinical use, always refer to primary sources.